Humoral immune response to COVID-19 vaccines in people with secondary progressive multiple sclerosis treated with siponimod

Mult Scler Relat Disord. 2022 Jan:57:103435. doi: 10.1016/j.msard.2021.103435. Epub 2021 Nov 29.

Abstract

Objective: The aim of this study is to determine a development of humoral response after COVID-19 vaccination in persons with secondary progressive multiple sclerosis (pwSPMS) on siponimod, compared to healthy controls (HC).

Methods: In 13 pwSPMS taking siponimod and 11 HC, testing for SARS-CoV2 antibodies was performed after vaccination against COVID-19.

Results: pwSPMS taking siponimod had a significantly lower titer of SARS-CoV2 antibodies compared to healthy controls (19.4 (0-250) vs. 250 (250), p>0.001). Two (15.4%) pwSPMS on siponimod had unmeasurable titers of SARS-CoV2-2 antibodies, while all HC had positive titers.

Conclusion: Although the results of this study are limited by a small sample size, results have consistently shown low titers of SARS-CoV-2 IgG after COVID-19 vaccinations in pwSPMS on siponimod.

Keywords: COVID-19; SARS-CoV-2 IgG antibody; Secondary progressive multiple sclerosis; Siponimod; Vaccines.

Publication types

  • Letter

MeSH terms

  • Antibodies, Viral
  • Azetidines
  • BNT162 Vaccine
  • Benzyl Compounds
  • COVID-19 Vaccines
  • COVID-19*
  • Humans
  • Immunity, Humoral
  • Multiple Sclerosis*
  • Multiple Sclerosis, Chronic Progressive* / drug therapy
  • RNA, Viral
  • SARS-CoV-2
  • Vaccination

Substances

  • Antibodies, Viral
  • Azetidines
  • Benzyl Compounds
  • COVID-19 Vaccines
  • RNA, Viral
  • BNT162 Vaccine
  • siponimod